Macular oedema
Drug Safety Update
January 2022: Brolucizumab (Beovu▼): risk of intraocular inflammation and retinal vascular occlusion increased with short dosing intervals
July 2020: Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection
August 2017: Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration
April 2016: Aflibercept (Zaltrap▼): minimising the risk of osteonecrosis of the jaw
NICE Guidance (see also drug specific links below)
NG82: Age-related macular degeneration, January 2018.
NG1022: Bevacizumab gamma for treating wet age-related macular degeneration, December 2024.
These drugs are for specialist use only and should be used in accordance with NICE guidance.
Triamcinolone acetonide preservative-free (Intracinol) is approved for vitreous visualisation during intraocular surgery and unlicensed (off label) use where necessary in macular oedema and non-infectious ocular inflammation.
| Pack |
|---|
| 1 pre-filled disposable injection |
| Pack |
|---|
| 1 vial |
| Pack |
|---|
| 1 vial |
| Pack |
|---|
| 1 vial |
| Pack |
|---|
| 1 pre-filled disposable injection |
| Pack |
|---|
| 1 vial |
- On Formulary Preferred
- On Formulary Second Line
- On Formulary Third Line
- Specialist Initiation
- Secondary Care Only
- Not Approved for Formulary